The company draws upon DeepMind's AlphaFold technology, which can be used to predict protein structures in the human body with high accuracy, allowing its researchers to find new target pathways for drug delivery.[6][7]
In January 2024, Isomorphic Labs partnered with Novartis AG and Eli Lilly and Company to work together on AI drug discovery and research.[9]
In May 2024, Google DeepMind and Isomorphic Labs announced the release of AlphaFold 3, freely available on the AlphaFold server for non-commercial research. AlphaFold 3 is not limited to predicting how proteins fold, it can also predict the interactions with molecules typically found in drugs such as ligands or antibodies, which is expected to significantly accelerate drug discovery.[10]